Akèy › Kansè pankreyas › North Carolina › Durham
Etid klinik pou Kansè pankreyas nan Durham, NC
24 etid pou Kansè pankreyas ap chèche patisipan nan sit nan ak bò kote Durham (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Vanguard Study: Testing a New Way to Screen for Cancer
Ap rekriteVolontè an sante akeyi
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
A Study of PHN-012 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- PHN-012-001 Site, Durham
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Ap rekriteFaz 3
- Duke Cancer Center, Durham
DESTINY-PANTUMOUR04
Ap rekriteEtid obsèvasyon
- Research Site, Durham
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Ap rekriteFaz 2/3
- UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill · 10 mi lwen
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13 mi lwen
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Ap rekriteFaz 3
- Duke Cancer Center, Durham
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Ap rekriteFaz 3
- Investigative Site US035, Chapel Hill · 10 mi lwen
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Ap rekriteFaz 1/2
- Duke University Medical Center, Durham
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Ap rekriteFaz 2
- Local Institution - 0100, Durham
Promoting CT Engagement for Pancreatic Cancer With App
Ap rekrite
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Ap rekriteEtid obsèvasyon
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
- University of North Carolina-Hillsborough Campus, Hillsborough · 13 mi lwen
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Ap rekriteFaz 2
- University of North Carolina, Chapel Hill · 10 mi lwen
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Ap rekriteFaz 1
- University of North Carolina - Gastroenterology and Hepatology, Chapel Hill · 10 mi lwen
- University of North Carolina, Chapel Hill · 10 mi lwen
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Ap rekriteFaz 3
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Ap rekriteFaz 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
Ap rekriteFaz 2
- Duke University Medical Center, Durham
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Ap rekriteFaz 1
- Duke Cancer Institute /ID# 276267, Durham
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Ap rekriteFaz 1
- Research Site, Durham
Autologous CAR-T Cells Targeting B7-H3 in PDAC
Ap rekriteFaz 1
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Ap rekriteFaz 1
- Duke Cancer Center, Durham
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
Ap rekriteFaz 1/2
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
Ap rekriteFaz 2
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi lwen
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Ap rekriteFaz 2
- University of North Carolina, Chapel Hill · 10 mi lwen
Etid Kansè pankreyas nan lòt vil
- Houston, TX61 etid
- New York City, NY60 etid
- Boston, MA43 etid
- Nashville, TN39 etid
- Los Angeles, CA35 etid
- St. Louis, MO33 etid
- Arlington, VA33 etid
- Baltimore, MD31 etid
- San Antonio, TX31 etid
- Philadelphia, PA26 etid
- Tampa, FL26 etid
- San Diego, CA24 etid
Lòt etid nan Durham
- Kansè nan tete64 etid
- Kansè (tout kalite)58 etid
- Kansè Poumon ki pa ti selil39 etid
- Myelom Miltip37 etid
- Leksemi mieloïd egi33 etid
- Kansè Metastatik33 etid
- Kansè pwostat32 etid
- Kansè poumon32 etid
- Kansè kolorektal28 etid
- Kansè ovè27 etid
- Lukemi lenfositè kwonik27 etid
- Ensifizyans kadyak26 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.